Crossmark

N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s12943-021-01398-4

Published Online: 2021-08-20

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Zhenchuan

Wang, Tingting

She, Yunlang

Wu, Kaiqing

Gu, Shaorui

Li, Lei

Dong, Chenglai

Chen, Chang

Zhou, Yongxin http://orcid.org/0000-0002-4093-5527
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81974053)

Shanghai Municipal Commission of Economy and Informatization (18441902300)
License Information

Text and Data Mining valid from 2021-08-20

Version of Record valid from 2021-08-20
More Information

Article History

Received: 27 April 2021

Accepted: 24 July 2021

First Online: 20 August 2021

Declarations

:

: This study was approved by the Medical Ethics Committee of Shanghai Tongji Hospital. Informed consent was obtained from each patient before enrollment in this study. All animal experiments were approved by the Animal Care and Use Committee of Shanghai Tongji Hospital and conducted in accordance with ethical standards.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below